Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) reported on Tuesday that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
The PDUFA target action date is set for 21 June 2024.
CIDP is a rare and serious autoimmune disease of the peripheral nervous system, with symptoms including fatigue, muscle weakness and a loss of feeling in the arms and legs that can get worse over time or may come and go. Without treatment, one-third of people living with CIDP will need a wheelchair.
The application is backed by data from the ADHERE study, demonstrating a 61% lower relapse risk with VYVGART Hytrulo compared to placebo. In the open-label Stage A of the study, two-thirds (67%) of patients showed evidence of clinical improvement following treatment with VYVGART Hytrulo.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment